STAT+: A turning point for pancreatic cancer patients
Recent advancements in pancreatic cancer treatment have been highlighted, particularly the promising results of daraxonrasib. Additionally, a Chinese lung cancer therapy continues to exceed expectations. These developments mark a significant turning point for patients battling these aggressive cancers.
- ▪Detailed results for daraxonrasib in pancreatic cancer were presented at ASCO.
- ▪A Chinese lung cancer therapy has shown continued success in clinical outcomes.
- ▪The article discusses the implications of these advancements for patients and the biotech industry.
Opening excerpt (first ~120 words) tap to expand
STAT PlusNewsletterThe Readout A turning point for pancreatic cancer patients Eli Lilly announces two China deals, Akeso’s lung cancer bispecific payoff, and more biotech news from The Readout Manage alerts for this article Email this article Share this article CNRI/SCIENCE PHOTO LIBRARY By Meghana KeshavanJune 1, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
